Two ways to make the same therapeutic protein, and a procurement decision that is easy to get wrong: treating plasma-derived and recombinant factor VIII as if they were simply two brands of the same thing. They are not. One starts from human plasma; the other is made without it. And in a number of markets — including China — that distinction is the difference between a product that can be imported and one that cannot.
This comparison is written for licensed importers, distributors and tender authorities — the people who have to know which factor VIII their market will admit, and why. It describes how each product is made, what that means for safety and registration, and ends with a decision guide for the procurement side.
The one-sentence difference
Plasma-derived factor VIII is a protein fractionated and purified from pooled human plasma. Recombinant factor VIII is the same protein produced by engineered cells using recombinant DNA technology, so it does not use human plasma as the starting material. Same target protein, different origin.
Side-by-side comparison
| Dimension | Plasma-derived factor VIII | Recombinant factor VIII |
|---|---|---|
| How it is made | Fractionated and purified from pooled human plasma | Produced by engineered cells via recombinant DNA technology |
| Starting material | Human plasma | No human plasma required |
| Target indication | Haemophilia A (factor VIII deficiency) | Haemophilia A (factor VIII deficiency) |
| Safety pathway | Donor screening plus viral inactivation steps | Cell-line based production without plasma starting material |
| Import status (China) | Restricted from import | Importable |
| Presentation (wanyoda) | 200 IU, powder and solvent | Not yet listed in the wanyoda portfolio |
| Approval number (wanyoda) | NMPA S20220023 | — (product line under consideration) |
| Manufacturer (wanyoda) | China Resources Boya | — |
The import-status row is the one that matters most at the buying desk: the same therapeutic protein can be lawful in one form and restricted in the other, depending on the market. A quotation that does not flag which form it is offering has not answered the question the tender is actually asking.
Why the difference matters at procurement
The distinction is not academic, and it shows up in three places the buying side has to get right.
Import eligibility, not just price
Before comparing quotations, confirm which form your market will admit. China restricts the import of plasma-derived factor VIII while recombinant factor VIII remains importable; other markets have their own rules. The first question is not "how much" but "which form is even lawful here".
Different registration pathways
Plasma-derived and recombinant products are different registered products with different dossiers. The registration that covers a plasma-derived factor VIII does not cover a recombinant one, and the import licence in the destination market names the specific product and its origin.
Supply and starting-material dependence
Plasma-derived factor VIII depends on the availability of fractionation-grade human plasma, which is a constrained, donor-dependent resource. Recombinant factor VIII is not tied to plasma collection capacity. This difference shapes long-term supply continuity and pricing, and it is a legitimate part of a procurement decision.
How to decide which one you need
The decision is resolved by two questions, in this order: what your market will admit, and what your tender specifies.
- If your market restricts plasma-derived factor VIII, the only lawful import option is recombinant — regardless of price.
- If your market admits both and the tender does not distinguish, confirm the origin (plasma-derived or recombinant) before quoting, because they are not interchangeable lines.
- If the requirement is ambiguous, stop and ask which form the specification names — the two are not alternatives, and guessing is how a non-compliant shipment is ordered.
Where the two genuinely do overlap is on the clinical target: both are factor VIII, and both serve haemophilia A. The difference that drives procurement is origin and the import rules that follow from it.
Frequently asked questions
What is the difference between plasma-derived and recombinant factor VIII?
Plasma-derived factor VIII is fractionated from pooled human plasma, while recombinant factor VIII is produced by engineered cells using recombinant DNA technology, without using human plasma as the starting material. They treat the same condition but are made differently and face different regulatory pathways.
Which one can be imported into my market?
It depends on the destination market's import rules, which vary and change. China, for example, restricts the import of plasma-derived factor VIII while recombinant factor VIII remains importable. Importers should confirm the specific product's eligibility with the destination authority before committing to a line.
Is one safer than the other?
Both undergo rigorous pathogen reduction and safety testing. Plasma-derived products are subject to donor screening and viral inactivation steps; recombinant products avoid the use of human plasma as a starting material. Each is registered and released through its own regulatory pathway.
Does wanyoda supply both types?
wanyoda currently supplies plasma-derived human coagulation factor VIII from China Resources Boya. A recombinant factor VIII product line is under consideration and not yet listed. Contact us for the latest portfolio status.
Do they need the same cold chain?
Yes, both are typically lyophilised with solvent for reconstitution and stored at 2–8 °C protected from light. The cold-chain and reconstitution requirements are broadly comparable, but the specific storage conditions must be read from each product's approved labelling.
Where to go next
- Human Coagulation Factor VIII (plasma-derived) — full specification and approval reference for the plasma-derived line.
- Product index — the full portfolio, by manufacturer.
- Documents a Chinese plasma supplier must provide — the document set that proves a plasma product is lawful and in-spec.